Flix partners DKMS to drive stem cell donor registration
Flix is partnering with DKMS, an international non-profit organisation dedicated to saving the lives of patients with blood cancer and blood disorders.
The long-term partnership aims to raise awareness and drive stem cell donor registration across six countries.
Through the collaboration entitled ‘Your journey could save a life’, DKMS and Flix aim to make registration as a potential stem cell donor as accessible and seamless as possible.
Travellers using onboard Wi-Fi on FlixBus in the United Kingdom (UK), Germany, Poland, Chile and the United States, as well as FlixTrain, will be guided to a dedicated landing page where they can begin the registration process with just a few clicks.
Every 27 seconds, someone somewhere in the world is diagnosed with blood cancer or a severe blood disorder. In the UK, a new blood cancer diagnosis occurs every 14 minutes.
While 30% of patients may find a matching stem cell donor within their family, the remaining 70% rely on unrelated donors, many of whom never find a match due to under-representation in donor registries. DKMS is working globally to diversify the donor pool to improve chances for all patients, especially those with rare genetic profiles.
“This collaboration shows how technology, mobility and purpose can come together” – André Schwämmlein, CEO of Flix
André Schwämmlein, CEO of Flix, said: “This collaboration shows how technology, mobility and purpose can come together. Flix connects people every day across borders, and now we’re helping connect potential lifesavers with patients around the world.”
“Through this partnership with Flix, we are reaching people in everyday moments and showing them how easy it is to take the first step toward saving a life” – Peter McCleave, DKMS UK Managing Director
Peter McCleave, DKMS UK Managing Director, said: “Through this partnership with Flix, we are reaching people in everyday moments and showing them how easy it is to take the first step toward saving a life. It’s a simple act that can make a real difference, not only for patients here in the UK but around the world.”